Global Wellness Times
SEE OTHER BRANDS

Global take on healthcare and wellness news

Global Wellness Times: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Global Wellness Times.

Press releases published on June 1, 2025

The Emerging Role of Sodium Lactate in Clean-Label Food Preservation and Its Ripple Effect on Industrial Demand Patterns

The Emerging Role of Sodium Lactate in Clean-Label Food Preservation and Its Ripple Effect on Industrial Demand Patterns

Sodium Lactate Market shifts from pharma to clean-label food, personal care, and eco-packaging, driven by demand for natural, multifunctional ingredients. NEWARK, DE, UNITED STATES, June 2, 2025 /⁨EINPresswire.com⁩/ -- 𝐈𝐧𝐭𝐫𝐨𝐝𝐮𝐜𝐭𝐢𝐨𝐧: 𝐀 𝐐𝐮𝐢𝐞𝐭 𝐏𝐥𝐚𝐲𝐞𝐫 𝐢𝐧 𝐚 …

Nxera Pharma Achieves Development Milestone in Collaboration with Eli Lilly Targeting Metabolic Diseases

Nxera Pharma Achieves Development Milestone in Collaboration with Eli Lilly Targeting Metabolic Diseases

Tokyo, Japan and Cambridge, UK, 2 June 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that it has achieved a development milestone under its multi-target collaboration and license agreement with Eli Lilly and Company (“ …

TORRAS Personal Cooling with Coolify Series: A Tech-Driven Solution for Comfort, Wellness, and Women's Health

TORRAS Personal Cooling with Coolify Series: A Tech-Driven Solution for Comfort, Wellness, and Women's Health

LOS ANGELES, June 01, 2025 (GLOBE NEWSWIRE) -- As global temperatures continue to rise and daily comfort becomes a growing concern, TORRAS is making waves with its innovative Coolify series—a wearable air conditioner engineered to deliver rapid, personal …

Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML

Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML

– New Drug Application based on positive results from the Phase 2 KOMET-001 trial – – FDA assigns a Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2025 – – Potential first approval of a menin inhibitor for the treatment of adult …

PXG Marks 5th Year of Women’s Golf Month with Expanded #SheGolfs Invitation to Play Amid Historic Surge in Women’s Golf Participation

PXG Marks 5th Year of Women’s Golf Month with Expanded #SheGolfs Invitation to Play Amid Historic Surge in Women’s Golf Participation

Scottsdale, AZ, June 01, 2025 (GLOBE NEWSWIRE) -- PXG, under the direction of its Chief Marketing Officer (CMO) Renee Parsons, is proud to launch the fifth annual celebration of its #SheGolfs initiative for Women’s Golf Month this June. Anchored in a deep …

KONTAKTUM (former Berger Kommunkation) launches SignalDesk to Power Europe’s Top Wellness Brands

KONTAKTUM (former Berger Kommunkation) launches SignalDesk to Power Europe’s Top Wellness Brands

BERLIN, June 01, 2025 (GLOBE NEWSWIRE) -- After more than 15 years operating quietly under the name BERGER KOMMUNIKATION, one of Europe’s most trusted backend communication infrastructures has officially rebranded and relaunched as KONTAKTUM. KONTAKTUM …

Smile Scarsdale Family Dental Celebrates One Year of Smiles as Trusted Family Dentist in Scarsdale

Smile Scarsdale Family Dental Celebrates One Year of Smiles as Trusted Family Dentist in Scarsdale

SCARSDALE, NY, UNITED STATES, May 31, 2025 /⁨EINPresswire.com⁩/ -- Smile Scarsdale Family Dental is proud to celebrate its one-year anniversary of delivering exceptional family dental care to the Scarsdale community and surrounding areas. Since opening its …

Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025

Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025

Median DOR of 21.7 months with 80% of responders achieving a deep response (≥80% tumor shrinkage) Depth and durability translating to prolonged OS with median OS of 21.3 months and 2-year OS of 46% in HPV-negative HNSCC Conference call and webcast today at …

Blog Chicks Online Magazine Commence Features On Organising Winter Weddings & Events In Sydney

Blog Chicks Online Magazine Commence Features On Organising Winter Weddings & Events In Sydney

Australian lifestyle news web portal Blog Chicks commence publishing a series of features on tips for organising Sydney weddings …

Camfil Releases 2024 Sustainability Report Emphasizing Transparency, Circularity, and Climate Action

Camfil Releases 2024 Sustainability Report Emphasizing Transparency, Circularity, and Climate Action

Riverdale, NJ, June 01, 2025 (GLOBE NEWSWIRE) -- In a year defined by heightened global expectations around corporate climate accountability, Camfil, a global leader in clean air technology, has published its 2024 Sustainability Report. The document offers …

Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO

Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO

Data Highlights Transformative Promise of CAR T in Solid Tumors Phase 1 Trial with ALLO-316 Demonstrated Potential to Provide Meaningful Clinical Benefit in Patients with CD70 TPS ≥ 50% Advanced or Metastatic RCC A Single Dose of ALLO-316 Achieved a 31% …

Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

- RP1 plus nivolumab generated robust responses in both injected and non-injected lesions - - Deep/visceral injections, including into the liver and lung, resulted in numerically higher rates of response compared to superficial injections only and were …

Seer’s Proteograph Platform Enables Unprecedented 20,000-Sample Proteomics Study with Korea University to Develop AI-Driven Diagnostics for Cancers in Young Adults

Seer’s Proteograph Platform Enables Unprecedented 20,000-Sample Proteomics Study with Korea University to Develop AI-Driven Diagnostics for Cancers in Young Adults

First-of-its-kind study will use Seer’s next-generation workflow to identify early-onset cancer biomarkers and power deep, unbiased mass spectrometry-based proteomics Seer’s new Proteograph ONE Assay to accelerate analysis and reduce costs, making large- …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service